# Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells

EUN-MEE LEE[1*], SANGSU SHIN[1*], HWA JUN CHA[1], YOUNGMIN YOON[1], SEUNGHEE BAE[1],
JIN HYUK JUNG[1], SUN-MI LEE[1], SU-JAE LEE[3], IN-CHUL PARK[4], YOUNG-WOO JIN[5] and SUNGKWAN AN[1,2]

[1]Functional Genoproteome Research Centre, Konkuk University; [2]LIFEnGENE, Inc., Seoul 143-701; [3]Department of
Chemistry, Hanyang University, Seoul 133-791; [4]Laboratory of Functional Genomics, Korea Institute of Radiological
and Medical Sciences, Seoul 139-706; [5]Division of Radiation Effect Research,
Radiation Health Research Institute of KHNP, Seoul 132-703, Korea

**Abstract.** Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibitor (HDACI) with antitumor effects that is being explored as a therapeutic drug. However, it has been reported that non-small cell lung cancer (NSCLC) is resistant to HDACIs. MicroRNAs (miRNAs) are a key class of small, non-coding RNA molecules that modulate post-transcriptional regulation of gene expression in multi-cellular organisms. miRNA expression patterns are involved in deregulation of gene expression in human lung cancer. Here we identified miRNA expression profile changes in response to SAHA treatment in the human lung carcinoma cell line A549. We also examined potential mRNA targets of SAHA-responsive miRNAs by using a target prediction program. Using microarray analysis, we found 64 miRNAs with >2-fold expression changes in SAHA-treated A549 cells. Among them, two unique miRNAs were altered in 2.5 $\mu$M SAHA-treated cells, 31 unique miRNAs were altered in 5.0 $\mu$M SAHA-treated cells and 31 miRNAs were altered with both doses. These miRNAs are predicted to have several target genes related to angiogenesis, apoptosis, chromatin modification, cell proliferation and differentiation. In conclusion, we have identified a unique set of miRNAs and their expression profiles that are influenced significantly by SAHA in the A549 NSCLC cell line model, which might provide useful information for understanding the anticancer mechanism of SAHA.

---

*Correspondence to:* Dr Sungkwan An, Functional Genoproteome Research Centre, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Korea
E-mail: ansfgrc@konkuk.ac.kr

*Contributed equally

## Introduction

Several studies have shown that histone deacetylases (HDACs) regulate many cellular functions. Erroneous phenotypic changes such as developmental disorders and cancer can be caused by aberrant histone acetylation (1). The regulation of histone deacetylation by HDACs modulates transcriptional regulation (2). In addition, certain types of human cancers are associated with abnormal deacetylation (3). Histone deacetylase inhibitors (HDACIs) are emerging as the target of several anticancer agents, which affect tumor cell proliferation, differentiation and induction of cell death in diverse cancer types (4-12). Suberoylanilide hydroxamic acid (SAHA) is an HDACI, and has been studied in several phase I/II clinical trials as a therapeutic cancer drug (13,14). However, the antitumor mechanism of HDACIs is not completely understood. Many researchers have investigated the effects of HDACI treatment in cancer patients and have obtained variable results. Non-small cell lung cancer (NSCLC) has been shown to be resistant to HDACIs such as trichostatin A and SAHA (2,15). For this reason, NSCLC has been treated in combination with other antitumor agents (16).

MicroRNAs (miRNA) are small non-coding RNA molecules that modulate the post-transcriptional regulation of gene expression in multi-cellular organisms by complementary interaction with the 3'-untranslated regions (3'-UTR) of target mRNA (17-19). miRNA interaction influences protein expression by promoting the degradation or suppressing mRNA translation (20,21). Several studies have shown that only a few miRNA expression patterns have been involved in deregulation of gene expression in human lung cancer. The role of miRNAs are not completely understood, however several studies have shown a correlation between miRNAs and human lung cancer (22-24).

We hypothesized that SAHA treatment of lung cancer cells could affect miRNA expression, and it may clarify the antitumor effects of HDACIs. We investigated whether SAHA treatment influences miRNA expression profiles in A549 cells using miRNA microarray. We discovered changes in miRNA expression and identified SAHA-responsive miRNAs in A549 cells. In addition, the target genes of the

candidate miRNAs may provide valuable information for cancer research.

## Materials and methods

*Cell culture*. The tumorigenic NSCLC cell line A549 was cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), and antibiotics at 37˚C in a humidified chamber supplemented with 5% $CO_2$. One day before SAHA treatment, $4x10^5$ cells were seeded into 60-mm culture dishes.

*SAHA treatment*. SAHA (Alexis Biochemicals, MA, Switzerland) was dissolved in DMSO (Sigma, MO, USA) and added to A549 cultures at different concentrations (2.5 and 5.0 $\mu$M). DMSO was added to culture media as a control.

*RNA preparation*. Total RNA was extracted from cells using TRIzol reagent (Invitrogen, CA, USA) 24 h after SAHA treatment. For the microarray studies, the quality and concentration of the RNA samples was determined with an Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA) and an Ultrospec 3300 Pro UV/Visible Spectrophotometer (Amersham Biosciences, NJ, USA). The recommended RNA quality parameters for the microarray analysis are an OD 260/280 ratio in the range of 1.8-2.0, an OD 260/230 ratio greater than 1.8, an 18s/28s rRNA ratio in the range of 1.8-2.1, and an RNA integrity number (RIN) greater than 8.0.

*Microarray analysis of miRNA profiles*. The human miRNA microarray version 2 kit (Agilent Technologies) containing probes for 723 human and 76 viral miRNAs was adapted to analyze the expression profiles of miRNAs. Before hybridizing, 100 ng of total RNA including miRNAs was dephosphorylated with calf intestine alkaline phosphatase (CIP), and denatured by adding DMSO and heating. The dephosphorylated RNA was labeled with pCp-Cy3 by T4 RNA ligase, and the labeled RNA was purified with a Micro Bio-Spin P-6 column (Bio-Rad Laboratories, USA). The purified RNA was denatured and hybridized to the probes on the microarray at 55˚C, 20 rpm in the Agilent Microarray Hybridization Chamber (Agilent Technologies) for 20 h. The microarray slide was washed and scanned with the Agilent scanner to obtain the microarray image. The numerical data for the miRNA profiles were extracted from the image with the Feature Extraction program (Agilent Technologies). These data were analyzed with GeneSpring GX software version 7.3 (Agilent Technologies).

*Classification of miRNAs*. Among the total miRNAs probed on the microarray, 723 human miRNAs were selected for further analysis. The miRNAs whose flags were present in at least one sample were filtered and applied to the fold-change analysis. The fold-change analysis was conducted by a factor of 2-fold between 3 groups: A549 control and 2.5 $\mu$M and 5.0 $\mu$M of SAHA-treated A549.

*Target prediction of miRNAs*. Candidate miRNAs that changed more than 2-fold following SAHA treatment were chosen for target prediction and analyzed with miRBase Targets Version 5 on the Enright Lab (Wellcome Trust Sanger Institute) website (http://microrna.sanger.ac.uk/targets/v5/).

Human genes with experimentally verified functions related to angiogenesis, apoptosis, chromatin modification, cell proliferation and differentiation were selected from the Gene Ontology website (http://www. geneontology.org/). Finally, the genes predicted as targets of the candidate miRNAs and those selected based on gene ontology were aligned by their gene names. Genes appearing in both lists were chosen and listed.

## Results and Discussion

To determine whether SAHA treatment of A549 cells (human type II-like epithelial lung cells) affects changes in miRNA expression levels, we analyzed miRNA profiles using the Agilent human miRNA microarray version 2 kit. A total of 723 human miRNAs, excluding 76 human viral miRNAs, were selected to analyze miRNA profiles. Those human miRNAs were continually filtered with flags as present to obtain more defined data using Agilent Genespring software. We selected total 227 human miRNAs as a result of flag-filtration, and these expression profiles are shown in Fig. 1, sorted by SAHA concentration. The color closest to green reflects low expression levels, whereas red color indicates higher expression levels. Although the majority of miRNAs do not show expression changes, SAHA treatment influences certain miRNA expression levels.

To further confirm that miRNA expression patterns are affected by the SAHA dose, we analyzed 227 flagged miRNAs and removed those that did not demonstrate a 2-fold change in expression levels by comparing the control, 2.5 $\mu$M and 5.0 $\mu$M treated cells. A total of 64 miRNAs were selected for further study (Table I) and their expression profiles are shown in Fig. 2A. Two miRNAs were altered in 2.5 $\mu$M treated cells and 31 miRNAs showing considerable expression changes were found in 5.0 $\mu$M treated cells. Surprisingly, 31 miRNAs showing more than 2-fold expression changes in 2.5 $\mu$M treated cells were also identified in 5.0 $\mu$M treated cells (Fig. 2B). In addition, the number of up- or down-regulated miRNAs was derived from the expression patterns in each treated group. We found 24 up-regulated and 9 down-regulated miRNAs in 2.5 $\mu$M treated cells. We also found 48 up-regulated and 12 down-regulated miRNAs in 5.0 $\mu$M treated cells (Fig. 2C). Although not all miRNAs show similar regulation patterns in both treatments, we identified many miRNAs with 2-fold expression changes that were regulated by SAHA.

Inhibition or activation of angiogenic gene expression by HDACIs result in anti-angiogenic effects and modulate cell proliferation in a diverse number of cancer cells (25-27). HDACIs induce apoptosis and inhibit tumor cell growth by targeting genes related to chromatin modification (28,29). Thus, we performed target prediction of miRNAs with those genes. A total of 17 miRNAs with expression levels regulated by SAHA treatment in Table I were selected to identify potential target genes related to angiogenesis, apoptosis, chromatin modification and cell proliferation and differentiation. Nearly 1,000 latent targets of each miRNA (excluding miR-1227, which is not available in the program) were predicted using miRBase Target Version 5. We investigated related targets from the Gene Ontology website that were

Figure 1. miRNA expression profiles using microarray analysis. After flag-filtration, a total of 227 human miRNA expression levels are represented by color from $10^{-2}$ (green) to $10^3$ (red). The data were separated into three groups: control, 2.5 $\mu$M SAHA and 5.0 $\mu$M SAHA.



Figure 2. miRNA expression profiles that showed >2-fold change in comparison with each group after SAHA treatment. Selected miRNAs and their expression levels are indicated by color (A). The Venn diagram shows the expression patterns of several miRNAs that are influenced by SAHA dose. Altogether, 31 miRNAs are changed in both conditions (B). Among 64 miRNAs showing 2-fold change, the miRNAs demonstrate up- or down-regulation in each treatment. The number of miRNAs with increased or decreased expression in each treatment (C).

Table I. 64 miRNAs showing 2-fold expression changes after SAHA exposure.[a]

| Concentration of SAHA (μM) | miRNA profiles | | | | | |
|---|---|---|---|---|---|---|
| | Up | | | | Down | |
| | miRNA name | Fold change | miRNA name | Fold change | miRNA name | Fold change |
| 2.5 | hsa-let-7b* | 4.18 | hsa-miR-376a | 2.26 | hsa-miR-106a | 3.81 |
| | hsa-miR-1227 | 3.93 | hsa-miR-382 | 3.55 | hsa-miR-155 | 5.38 |
| | hsa-miR-124 | 5.79 | hsa-miR-409-3p | 4.2 | hsa-miR-193b* | 17.98 |
| | hsa-miR-126 | 12.39 | hsa-miR-450a | 3.61 | hsa-miR-30c-1* | 11.8 |
| | hsa-miR-127-3p | 2.48 | hsa-miR-542-3p | 2.74 | hsa-miR-345 | 27.51 |
| | hsa-miR-129-3p | 22.6 | hsa-miR-595 | 2.1 | hsa-miR-516a-5p | 3.65 |
| | hsa-miR-132 | 34.02 | hsa-miR-629 | 2.63 | hsa-miR-593 | 15.67 |
| | hsa-miR-183 | 2.54 | hsa-miR-654-3p | 2.08 | hsa-miR-877* | 10.32 |
| | hsa-miR-22* | 2.76 | hsa-miR-660 | 26.58 | hsa-miR-936 | 12.91 |
| | hsa-miR-24-1* | 2.93 | hsa-miR-769-5p | 2.9 | | |
| | hsa-miR-30e* | 2.71 | hsa-miR-9* | 3.86 | | |
| | hsa-miR-337-5p | 3.52 | hsa-miR-96 | 2.19 | | |
| 5.0 | hsa-let-7b* | 9.29 | hsa-miR-379 | 2.6 | hsa-miR-106a | 5.69 |
| | hsa-miR-1227 | 8.47 | hsa-miR-381 | 2.4 | hsa-miR-17* | 2.3 |
| | hsa-miR-124 | 225 | hsa-miR-382 | 6.35 | hsa-miR-193b* | 2.45 |
| | hsa-miR-126 | 11.46 | hsa-miR-383 | 2.07 | hsa-miR-200b | 2.79 |
| | hsa-miR-127-3p | 3.7 | hsa-miR-409-3p | 7.71 | hsa-miR-30c-1* | 7.36 |
| | hsa-miR-129-3p | 33.95 | hsa-miR-425 | 2.12 | hsa-miR-30e* | 4.62 |
| | hsa-miR-132 | 55.34 | hsa-miR-432 | 2.24 | hsa-miR-345 | 2.77 |
| | hsa-miR-134 | 2.02 | hsa-miR-450a | 3.63 | hsa-miR-516a-5p | 3.08 |
| | hsa-miR-140-5p | 2.01 | hsa-miR-487b | 2.3 | hsa-miR-548c-3p | 4.95 |
| | hsa-miR-182 | 2.09 | hsa-miR-502-3p | 2.73 | hsa-miR-760 | 2.09 |
| | hsa-miR-183 | 2.76 | hsa-miR-542-3p | 2.44 | hsa-miR-92a | 2.03 |
| | hsa-miR-197 | 2.5 | hsa-miR-574-3p | 2.07 | hsa-miR-99b | 2.16 |
| | hsa-miR-206 | 2.64 | hsa-miR-595 | 2.19 | | |
| | hsa-miR-22* | 3.25 | hsa-miR-629 | 3.57 | | |
| | hsa-miR-24-1* | 2.25 | hsa-miR-654-3p | 3.15 | | |
| | hsa-miR-299-3p | 2.26 | hsa-miR-660 | 33.41 | | |
| | hsa-miR-337-5p | 4.84 | hsa-miR-744* | 2.7 | | |

[a]The list was selected to show only those miRNAs representing >2-fold expression change after flag sorting.

separated into four groups: angiogenesis (23 genes), apoptosis (178 genes), chromatin modification (20 genes) and cell proliferation and differentiation (75 genes). The overlapping genes that were acquired through the comparison between those from the miRBase Target and those from the Gene Ontology are listed in Table II. It is important to note that each miRNA has several target mRNAs, and each target could be controlled by many miRNAs (30). In this analysis, all miRNAs in the list have at least one of their predicted target genes related to the four groups, and some of them have more than one target gene. Among 23 angiogenic genes identified by Gene Ontology, miRBase Targets predicted 14 genes that

could be regulated by 17 of the candidate miRNAs. We found 94 genes associated with apoptosis, six genes associated with chromatin modification and 23 genes associated with cell proliferation and differentiation.

In conclusion, our data indicate that SAHA treatment of A549 cells causes changes in the miRNA expression profile. Although SAHA has been successfully shown to be an effective anticancer agent, the mechanism by which this occurs is not fully understood. However, this study shows that certain miRNAs undergo changes in response to SAHA and may differentially regulate their target genes, which may further clarify the role of SAHA in cancer therapy.

Table II. miRNA target genes dependent on concentration of SAHA from Table I.

| miRNA name | Functions of target genes | | | |
| | Angiogenesis | Apoptosis | Chromatin modification | Cell proliferation and differentiation |
| --- | --- | --- | --- | --- |
| hsa-let-7b* | EPGN, MYH9, SCG2 | BFAR, CHEK2, DLC1, FASLG, HBXIP, PMAIP1, SAP30BP, SCG2, SON, TP53BP2 | INOC1 | DLC1 |
| hsa-miR-106a | RNH1 | BAX, BCL2L11, BNIPL, HBXIP, NUP62, P2RX4, PPP3R1, TNFRSF10B | - | BNIPL, NUP62 |
| hsa-miR-1227 | N/A | N/A | N/A | N/A |
| Hsa-miR-124 | HTATIP2, SPHK1 | AGT, APOE, BAX, CADM1, CD27, ERCC3, GRIK2, HTATIP2, RELA, SIVA1, TGFB1, TNFSF15 | - | - |
| hsa-miR-127-3p | - | AIFM3, BAD, BCL6, NLRP1, PPP3CC | HTATIP | ING5 |
| hsa-miR-129-3p | - | ANGPTL4, BAD, CASP8, CDKN1B, CDKN2C, CRYAB, DEDD2, ERCC3 IFI16, ING4, PPP3R1, SFN, STK4, TP53 | - | - |
| hsa-miR-132 | AMOT | BCL2L11, CASP8, GHRL, HIP1, IL6, LCK, PEA15, PML, RASA1, YWHAB | TNP1, PML | APC, ENPEP, ENPP7 |
| hsa-miR-183 | - | CASP10, DFFB, GRIK2, HIP1, IL12B, LCK, PPP3CC, SRA1, TCF7L2 | HDAC10 | BTG1, EPO, RASGRP4, SRA |
| hsa-miR-22* | AGGF1, HHEX | AIFM3, CASP8, CIDEC, FASLG, IL6, RTKN, TP53BP2, TRADD | - | EDN2 |
| hsa-miR-337-5p | - | AGT, ANGPTL4, BCL10, HBXIP, HSPA5, SFN, TCF7L2, TP53BP2 | - | - |
| hsa-miR-376a | - | CADM1, CASP8, FAS, HBXIP, IL6, PPP3CC, TERF1 | - | GLI2, PCAF |
| hsa-miR-382 | - | ADAMTSL4, CD40LG, CDKN2C, GLO1, HSPD1, IFI16, IFNG, PPP3CC | RSF1 | CDKN2C, DERL2, MYC, RERG |
| hsa-miR-409-3p | COL4A3, NCL | AKT1, COL4A3, DNAJB6, ERCC3, TCF7L2 | - | EPO |
| hsa-miR-629 | ANGPTL3, COL4A3, EPGN | ALB, APOE, COL4A3, DLC1, GRIK2, RTKN, TCF7L2 | - | DLC1, ENPEP MYC, POLA1 |
| hsa-miR-654-3p | - | ACIN1, CASP10, CDKN2A, NDUFA13, P2RX4, RPS3, TNF | - | - |
| hsa-miR-660 | - | ADAMTSL4, CADM1, CECR2, HIP1, IFI16, IFT57, LCK, LGALS12, UBE4B | - | RERG |
| hsa-miR-769-5p | - | BCL2L11, CRYAA, ING4, NDUFS1, NLRP1, PCBP4, RELA, TBX3 | - | EPO, GLI2, ING4, MEN1, TBX3 |
| hsa-miR-96 | IL17F, NCL, PROK2 | AIFM3, CRYAB, DYNLL1, GRIK2, LCK, P2RX4, PCBP4, PROK2, SON, SRA1 | HDAC10, HTATIP | PROK2, SRA1 |

N/A, not applicable.

## Acknowledgements

## References

 1. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW and Kornhuber B: Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7: 766-773, 1996.
 2. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y and Jones DR: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the akt pathway. J Biol Chem 278: 18980-18989, 2003.
 3. Verdin E, Dequiedt F and Kasler HG: Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293, 2003.
 4. Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168, 2004.
 5. McLaughlin F and La Thangue NB: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68: 1139-1144, 2004.
 6. Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents. Mol Pharmacol 68: 917-932, 2005.
 7. Kelly WK and Marks PA: Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005.
 8. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
 9. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
10. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
11. Rasheed WK, Johnstone RW and Prince HM: Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16: 659-678, 2007.
12. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
13. Kelly WK, Richon WM, O'Connor O, *et al*: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588, 2003.
14. Kelly WK, Richon VM, O' Connor OA, *et al*: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol 23: 3923-3931, 2005.
15. Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128: 740-748, 2004.
16. Kuljaca S, Liu T, Tee AE, Haber M, Norris MD, Dwarte T and Marshall GM: Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer 6: 68, 2007.
17. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126, 2007.
18. Luthra R, Singh RR, Luthra MG, *et al*: MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 27: 6667-6678, 2008.
19. Raver-Shapira N, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743, 2007.
20. Ambros V and Chen X: The regulation of genes and genomes by small RNAs. Development 134: 1635-1641, 2007.
21. Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8: 23-36, 2007.
22. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
23. Eder M and Scherr M: MicroRNA and lung cancer. N Engl J Med 352: 2446-2448, 2005.
24. Nana-Sinkam SP and Geraci MW: MicroRNA in lung cancer. J Thorac Oncol 1: 929-931, 2006.
25. Kwon HJ, Kim MS, Kim MJ, Nakajima H and Kim KW: Histone deacetylase inhibitor fk228 inhibits tumor angiogenesis. Int J Cancer 97: 290-296, 2002.
26. Deroanne CF, Bonjean K, Servotte S, *et al*: Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436, 2002.
27. Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J Jr: Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799, 2004.
28. Subramanian C, Opipari Jr AW, Bian X, Castle VP and Kwok RP: Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 4842-4847, 2005.
29. Cohen HY, Lavu S, Bitterman KJ, *et al*: Acetylation of the c terminus of ku70 by cbp and pcaf controls bax-mediated apoptosis. Mol Cell 13: 627-638, 2004.
30. John B, Enright AJ, Aravin A, Tuschi T, Sander C and Marks D: Human microRNA targets. PLoS Biol 2: E363, 2004.